Z-1018 is under clinical development by Dynavax Technologies and currently in Phase I for Herpes Zoster (Shingles). According to GlobalData, Phase I drugs for Herpes Zoster (Shingles) have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Z-1018’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Z-1018 is under development for the prevention of herpes zoster (shingles) infection. The vaccine candidate is comprised of herpes zoster antigen-glycoprotein E (gE) with a toll-like receptor 9 (TLR9) agonist adjuvant (CpG 1018). It acts by targeting varicella zoster virus envelop glycoprotein E. It is administered by parenteral route.
Dynavax Technologies overview
Dynavax Technologies (Dynavax) is an biopharmaceutical company that develops novel vaccines based on Toll-like receptor(TLR) biology and also focuses on Various infectious and inflammatory diseases. The company marketed product Heplisav-B is an adult vaccine which is indicated for the prevention of hepatitis B. The company’s pipeline focuses on combining the innate immune response with other immunomodulatory agents for the treatment of cancer. Its ongoing studies include DV2-ZOS-01 for immune-mediated, herpes zoster, and anaphylaxis events; DV2-HBV-27 for the pregnancy registry. Dynavax also has a vaccine candidate, DV2-TDAP-01 adjuvant, for pertussis. The company operates through its subsidiaries in Germany and India. Dynavax is headquartered in Emeryville, California, the US.
For a complete picture of Z-1018’s drug-specific PTSR and LoA scores, buy the report here.